Posts Categorized: MS News

NICE pauses final decision on ocrelizumab for primary progressive MS

Source MS Trust: NICE has announced that it is pausing the publication of final guidance for ocrelizumab for primary progressive multiple sclerosis. The final decision was due to be published on the NICE website on 31 October and would have rejected ocrelizumab as an NHS treatment for primary progressive MS on the grounds of cost-effectiveness. The MS Trust now understands that… Read more »

Novartis bets priority review voucher on its next big multiple sclerosis drug — eyes US, EU approvals in ’19

Source Endpoints News: One of Novartis’ top late-stage candidates for multiple sclerosis is now under review on both sides of the Atlantic. Having stoked enthusiasm for siponimod through a solid Phase III data package, the Swiss drugmaker traded in a priority review voucher at the FDA for an expedited action date around March of next year…. Read more »

Former watchdog chief labels disabled benefits process a ‘hostile environment’

Source The Guardian: Andrew McDonald, who chaired Independent Parliamentary Standards Authority, says the system is ‘Kafka-esque’ A former top civil servant has criticised the disability benefits assessment system as a “hostile environment” after being told he was ineligible for support despite having Parkinson’s and terminal prostate cancer. Andrew McDonald, 56, who ran the parliamentary body overseeing… Read more »

Medical Cannabis To Be Available On Prescription ‘Within Weeks’

Source Huffington Post: Medical cannabis will be available on prescription in the UK within a month, according to The Telegraph. The Home Office is expected to announce the “rescheduling” of cannabis-derived medicines in Parliament within a fortnight, lifting restrictions which mean that until now it has only been allowed in the most exceptional circumstances within a matter… Read more »

Physical Activity Decreases Vascular Comorbidities in Multiple Sclerosis

Source Neurology Advisor: Increased levels of physical activity may lead to decreased vascular risk profiles in patients with multiple sclerosis, according to a literature review published in Multiple Sclerosis and Related Disorders. Researchers in this review searched for published articles in 5 major databases for studies involving physical activity, sedentary lifestyles, or exercise training and the impact these… Read more »

“Diagnose and adios”. This was the phrase used to describe the management of multiple sclerosis (MS) up until the mid-1990s

Source MS Trust: The Risk Sharing Scheme: What is it and how has it made a difference for people with MS? Diagnose and adios “Diagnose and adios”. This was the phrase used to describe the management of multiple sclerosis (MS) up until the mid-1990s. It’s hard to fathom today, but back then neurologists had little to… Read more »

Get around with these apps for accessible travel

Source Independent Living: Travelling around the UK is certainly not easy for wheelchair users. Many wheelchair users have, in fact, faced prejudice while attempting to get around independently. Comedian, Tanyallee Davis, recently suffered and expressed her humiliation on a train journey during which the driver insisted she move from the disabled space she was rightfully occupying,… Read more »

Making a lasting power of attorney has never been easier!

Making a lasting power of attorney for your health and wellbeing and financial affairs has never been easier! You may never need it, but it’s a good idea to plan ahead just in case! The government online service will guide you through the process to create a lasting power of attorney. Find out more here.

Encouraging news for people with primary or secondary progressive MS

Source F1000 Prime: Fox et al. present the results of the eagerly awaited SPRINT-MS trial – a multi-centre phase II double blinded placebo controlled study of ibudilast in decreasing brain atrophy in progressive forms of multiple sclerosis (MS). Ibudilast was previously trialled in relapsing MS and whilst it did not prevent the reduction of new T2… Read more »